NCT04340986

Recruiting

Cohort of Patients With Hepatocellular Carcinoma or Cholangi...

Assistance Publique - Hôpitaux de Paris Source

Compare

Other study identifiers

Sponsor study identifier

APHP190473

Secondary identifiers

IDRCB 2019-A01679-48

OTHER · ANSM

Study Type

observational

Estimated enrollment

1,250

Locations

1 country

Sites

1

Timeline

Study Start

September 2, 2020

Actual (reported)

Primary Completion

September 2030

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

September 2030

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

The main objective is to describe the evolution of patients treated for a primary malignant hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: recruiting
Estimated enrollment: 1,250 participants
Study completion date: September 2030
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
April 7, 2020
Actual (reported)
First Posted
April 10, 2020
Actual (reported)
Study Start
September 2, 2020
Actual (reported)
Primary Completion
September 2030
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
September 2030
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: June 20, 2024
Status Verified: June 2024
Last Update Submitted: June 18, 2024

Conditions

Cholangiocarcinoma Hepatocellular Carcinoma

Keywords

hepatocellular carcinomacholangiocarcinomacohort

Outcome Measures

Primary Outcomes (1)

Overall survival
Hepatocellular carcinoma and Cholangiocarcinoma : Overall survival is defined as the survival 5 years after the inclusion.
5 years

Secondary Outcomes (3)

Overall survival
5 years
Disease free survival
2 and 5 years
Progression time under chemotherapy
Time of progression under chemotherapy up to 5 years

Study Arms (2)

patients with Hepatocellular carcinoma

patients with Cholangiocarcinoma

Eligibility Criteria

Age18 Years+

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

All patients with hepatocellular carcinoma or cholangiocarcinoma treated in Saint-Antoine hospital

You may qualify if:

Age ≥ 18 years olds

Sponsors & Collaborators

Assistance Publique - Hôpitaux de Paris
Otherlead

Study Sites (1)

Serviec hépatologie-Hôpital Saint Antoine

Paris, 75012, France

RECRUITING

Marie LEQUOY, MDCONTACT+330149283154 marie.lequoy@aphp.fr

MeSH Terms

Conditions

CholangiocarcinomaCarcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

Marie LEQUOY, MD
AssistancePublique-Hôpitaux de Paris
PRINCIPAL INVESTIGATOR

Central Study Contacts

Marie LEQUOY, MD

CONTACT

+330149283154 marie.lequoy@aphp.fr

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 7, 2020

First Posted

April 10, 2020

Study Start

September 2, 2020

Actual (reported)

Primary Completion

September 2030

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

NCT02232633

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Phase 2Completed

NCT04420026

Study of Automatic Image Fusion of a CT Volume With Ultrasound During Percutaneous Ablation Treatment of Hepatic Tumors

Not ApplicableCompleted

NCT04823754

Perception of the Doctor/Patient Relationship, Disease and Treatment Among Physicians and Their Patients Treated With Systemic Therapy for Hepatocellular Carcinoma "PERCEPTION1"

Completed

NCT05044676

Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma

Terminated

NCT02917759

Liver and Biliary Tumor Tissue Registry

Terminated

NCT04391348

Combination PET With 18F-fluorodeoxyglucose (18F-FDG) and 18 F-choline in Patient With HCC

Not ApplicableCompleted

Medical care in Nephrology department since 2015

Cholangiocarcinoma:

\- Histologically and cytologically documented cholangiocarcinoma, regardless of the stage of the disease

Hepatocellular carcinoma:

Hepatocellular carcinoma at any stage of the disease, presenting the diagnostic criteria according to the diagnostic criteria of Barcelona : Tumor of more than 1 cm, developed on cirrhosis liver with arterial phase hyperenhancement and washout in the portal venous or delayed phases on CT and MRI

Hepatocellular histologically documented

You may not qualify if:

\- Lack of patient non-opposition

Contact the study team to confirm eligibility.

Study Completion

September 2030

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

June 20, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT04340986
Data provider: ClinicalTrials.gov
Source updated: 2024-06-20
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:39:37 UTC

Locations

FR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (2)

patients with Hepatocellular carcinoma

patients with Cholangiocarcinoma

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations